Gao Ping, Gao Pan, Zhao Jinjing, Shan Shengshuai, Luo Wei, Slivano Orazio J, Zhang Wei, Tabuchi Akiko, LeMaire Scott A, Maegdefessel Lars, Shen Ying H, Miano Joseph M, Singer Harold A, Long Xiaochun
Department of Molecular and Cellular Physiology, Albany Medical College, Albany, NY, USA.
Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Redox Biol. 2021 May;41:101903. doi: 10.1016/j.redox.2021.101903. Epub 2021 Feb 20.
Abdominal aortic aneurysm (AAA) is a catastrophic disease with little effective therapy. Myocardin related transcription factor A (MRTFA, MKL1) is a multifaceted transcription factor, regulating diverse biological processes. However, a detailed understanding of the mechanistic role of MKL1 in AAA has yet to be elucidated. In this study, we showed induced MKL1 expression in thoracic and abdominal aneurysmal tissues, respectively in both mice and humans. MKL1 global knockout mice displayed reduced AAA formation and aortic rupture compared with wild-type mice. Both gene deletion and pharmacological inhibition of MKL1 markedly protected mice from aortic dissection, an early event in Angiotensin II (Ang II)-induced AAA formation. Loss of MKL1 was accompanied by reduced senescence/proinflammation in the vessel wall and cultured vascular smooth muscle cells (VSMCs). Mechanistically, a deficiency in MKL1 abolished AAA-induced p38 mitogen activated protein kinase (p38MAPK) activity. Similar to MKL1, loss of MAPK14 (p38α), the dominant isoform of p38MAPK family in VSMCs suppressed Ang II-induced AAA formation, vascular inflammation, and senescence marker expression. These results reveal a molecular pathway of AAA formation involving MKL1/p38MAPK stimulation and a VSMC senescent/proinflammatory phenotype. These data support targeting MKL1/p38MAPK pathway as a potential effective treatment for AAA.
腹主动脉瘤(AAA)是一种几乎没有有效治疗方法的灾难性疾病。心肌相关转录因子A(MRTFA,MKL1)是一种多面转录因子,可调节多种生物学过程。然而,对MKL1在AAA中的作用机制的详细了解尚待阐明。在本研究中,我们分别在小鼠和人类的胸主动脉瘤和腹主动脉瘤组织中发现了MKL1表达上调。与野生型小鼠相比,MKL1基因完全敲除的小鼠腹主动脉瘤形成和主动脉破裂减少。基因缺失和MKL1的药理学抑制均能显著保护小鼠免于主动脉夹层形成,这是血管紧张素II(Ang II)诱导的腹主动脉瘤形成的早期事件。MKL1缺失伴随着血管壁和培养的血管平滑肌细胞(VSMC)中衰老/促炎反应的减少。从机制上讲,MKL1缺乏消除了腹主动脉瘤诱导的p38丝裂原活化蛋白激酶(p38MAPK)活性。与MKL1类似,VSMC中p38MAPK家族的主要亚型MAPK14(p38α)缺失也抑制了Ang II诱导的腹主动脉瘤形成、血管炎症和衰老标志物表达。这些结果揭示了一条涉及MKL1/p38MAPK刺激和VSMC衰老/促炎表型的腹主动脉瘤形成分子途径。这些数据支持将MKL1/p38MAPK途径作为腹主动脉瘤的一种潜在有效治疗靶点。